Orbital Therapeutics

Executive Summary

Orbital Therapeutics is a preclinical-stage biotechnology company advancing a next-generation RNA platform to develop durable and programmable medicines for infectious diseases, oncology, and genetic disorders. Founded in 2022 and headquartered in Cambridge, Massachusetts, the company has raised $270 million in total funding, reflecting strong investor confidence in its synthetic biology approach to engineer novel RNA modalities, delivery systems, and manufacturing processes. By focusing on enhancing RNA stability, tissue targeting, and scalable production, Orbital aims to overcome key limitations of current RNA therapeutics and vaccines. With a robust balance sheet and a clear strategic focus on platform differentiation, Orbital is well-positioned to advance multiple programs toward clinical development in the coming years. However, as a private preclinical company, its valuation and clinical timelines remain opaque, and success hinges on successful IND filings and initial proof-of-concept data.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead oncology program50% success
• H1 2026Lead optimization data for infectious disease vaccine candidate70% success
• 2026Partnership or collaboration announcement for RNA delivery platform60% success